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Background: Staphylococcus aureus and Pseudomonas aeruginosa are often found together in the airways of cystic
fibrosis (CF) patients. It was previously shown that the P. aeruginosa exoproduct 4-hydroxy-2-heptylquinoline-
N-oxide (HQNO) suppresses the growth of S. aureus and provokes the emergence of small-colony variants (SCVs).
The presence of S. aureus SCVs as well as biofilms have both been associated with chronic infections in CF.
Results: We demonstrated that HQNO stimulates S. aureus to form a biofilm in association with the formation of
SCVs. The emergence of SCVs and biofilm production under HQNO exposure was shown to be dependent on the
activity of the stress- and colonization-related alternative sigma factor B (SigB). Analysis of gene expression revealed
that exposure of a prototypical S. aureus strain to HQNO activates SigB, which was leading to an increase in the
expression of the fibronectin-binding protein A and the biofilm-associated sarA genes. Conversely, the quorum
sensing accessory gene regulator (agr) system and the a-hemolysin gene were repressed by HQNO. Experiments
using culture supernatants from P. aeruginosa PAO1 and a double chamber co-culture model confirmed that
P. aeruginosa stimulates biofilm formation and activates SigB in a S. aureus strain isolated from a CF patient.
Furthermore, the supernatant from P. aeruginosa mutants unable to produce HQNO induced the production of
biofilms by S. aureus to a lesser extent than the wild-type strain only in a S. aureus SigB-functional background.
Conclusions: These results suggest that S. aureus responds to HQNO from P. aeruginosa by forming SCVs and
biofilms through SigB activation, a phenomenon that may contribute to the establishment of chronic infections in
CF patients.
Background
Although cystic fibrosis (CF) is fundamentally a genetic
disorder, the majority of patients with CF may ulti-
mately succumb to respiratory failure subsequent to
chronic bacterial infections [1]. In early childhood, lungs
of CF patients are often infected with Staphylococcus
aureus and Haemophilus influenzae,b u tt h e s eo r g a n -
isms are usually outnumbered by Pseudomonas aerugi-
nosa as patients become older. However, S. aureus often
persists in the airways of CF patients and the role of S.
aureus in the progression of CF patients to respiratory
failure is not yet understood whereas infections with
P. aeruginosa is considered as one of the main factors
for a decline in lung function and mortality [1]. Interest-
ingly, both organisms are commonly co-isolated from
CF airways [2,3].
Infections with mixed microbial communities are com-
mon, although very little is known about the importance
and the impact of interspecies interactions [4]. It is now
becoming obvious that the different bacteria found in CF
airways interact together in several different ways [5-10].
One possibility is that polymicrobial interactions influ-
ence pathogenic processes such as biofilm formation
[1,9]. Accordingly, the biofilm lifestyle is now recognized
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and it is thought that cell-to-cell interspecies signals play
a role in the control of this behavior [11].
It has recently been shown that prolonged growth of
S. aureus with physiological concentrations of the
P. aeruginosa exoproduct 4-hydroxy-2-heptylquinoline-
N-oxide (HQNO) selects for a sub-population of slow-
growing respiratory deficient S. aureus named small-col-
o n yv a r i a n t s( S C V s )[ 2 ] .T h er e s p i r a t o r yd e f i c i e n c yo f
SCVs provides resistance to aminoglycoside antibiotics,
which can contribute to microbial persistence during
antibiotherapy [12]. Furthermore, it has been recently
demonstrated that SCV selection is a survival strategy of
S. aureus against P. aeruginosa [13]. S. aureus SCVs are
often isolated from chronic infections [12], as in the
case of lung infections of CF patients [14-16]. Several
studies have shown that S. aureus SCVs possess an
increased capacity to invade and persist in host cells
[14,15,17], which is thought to confer the bacterium
protection against the immune system and the action of
antibiotics [17,18]. Using SCVs isolated from cystic
fibrosis patients, we have previously demonstrated that
the alternative transcription sigma factor B (SigB) influ-
ences the expression of several virulence factors and is
associated with an increased ability to adhere, invade
and persist within host cells [15,19]. Furthermore, our
more recent results suggest that SigB is involved in the
emergence of SCVs under aminoglycoside pressure [20],
which suggests that the appearance of SCVs may be a
regulated process influenced by environmental cues.
Our current hypothesis is that SigB plays an important
role in the establishment of chronic and difficult-to-
treat S. aureus infections.
SigB is involved in the response to environmental
stresses such as during stationary phase, heat exposure
and change in osmotic pressure [21]. Moreover, the
activity of SigB positively influences the expression of
several cell-surface proteins whereas it down-regulates a
variety of toxins [22], which suggest an important role
for SigB in pathogenesis. The effect of SigB on virulence
gene expression can be direct or indirect, since the
genes regulated by SigB also include at least another
global regulator of virulence, sarA (Staphylococcal
accessory regulator) [22,23]. SarA modulates the expres-
sion of several virulence factors either by stimulating
RNAIII transcription or by pathway(s) independent of
the agr (accessory gene regulator) system [24]. In turn,
it is proposed that the quorum-sensing agr system con-
trols the transition from colonization to dissemination
by up-regulating the expression of several exotoxins and
proteolytic enzymes and by repressing the expression of
cell-surface proteins involved in colonization [25]. agr
[26], SigB [27,28] and SarA [29] are known to influence
the formation of biofilms by S. aureus.
At least two different mechanisms of biofilm formation
exist in S. aureus [26,29-33]. The first mechanism implies
the production of the polysaccharide intercellular adhesin
(PIA), which requires the ica gene cluster, whereas the
second mechanism is ica-independent. With opposite
effects, SarA and agr are both involved in the ica-inde-
pendent mechanism of biofilm formation. SarA is
thought to be indirectly required for the initial attach-
ment step to biological matrices [29,32,33], while agr is
controlling the dispersal process of biofilms [26].
Recently, Lauderdale et al. [30] have shown that SigB is
an essential regulator of the ica-independent biofilm for-
mation and suggested that SigB acts upstream of the agr
system, allowing the formation of biofilm to be regulated
as a function of environmental factors. Noteworthy, bio-
films have been linked to chronic infections, especially in
the case of those found in the airways of CF patients
[1,34], and an increased formation of biofilms has been
associated with the SCV phenotype [20,35].
The aim of this study was to investigate the associa-
tion between the activity of SigB, the emergence of
SCVs and biofilm production in S. aureus when exposed
to P. aeruginosa HQNO.
Results
HQNO inhibits the growth of normal strains and provokes
the emergence of SCVs in S. aureus
Fig. 1 confirms that HQNO suppresses the growth of
S. aureus and causes the emergence of SCVs. Isolates
CF1A-L and CF1D-S are two related strains co-isolated
from a CF patient which have a normal and a SCV phe-
notype, respectively (see Methods). At a concentration
of 10 μg/ml, HQNO significantly attenuated the growth
of CF1A-L (P < 0.01 from 6 to 12 h of growth; two-way
ANOVA followed by a Bonferroni’s post test) whereas
HQNO had no apparent effect on the growth of CF1D-
S which was already significantly slower than that of
CF1A-L in the absence of HQNO (P < 0.001 from 6 to
12 h of growth; two-way ANOVA followed by a Bonfer-
roni’s post test) (Fig. 1A). Similar observations were also
reproduced with other strains (two normal and one
SCV; data not shown). Fig. 1B shows that an overnight
treatment with HQNO provokes the emergence of SCVs
from CF1A-L, as determined by plating the culture on
solid medium containing a concentration of gentamicin
selective for the SCV phenotype. Very little or no SCV
were detected on gentamicin plates when cultures were
not exposed to HQNO (Fig. 1B). Hence, this technique
allowed detection and quantification of SCVs emerging
during the growth of normal bacteria exposed or not to
HQNO. This approach was thus used to distinguish the
transitory suppression of growth of normal S. aureus by
HQNO from the emerging slow-growing SCVs for
which gentamicin resistance and slow growth persist
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of HQNO/ml significantly increased the presence of
SCVs in cultures of the prototypical strains ATCC
29213, Newman and Newbould as well as of the other
normal strains isolated from CF patients CF03-L, CF07-
L and CF1A-L. Differences in HQNO-mediated SCV
emergence between strains were not significant, except
between ATCC 29213 and Newbould (P < 0.01; one-
w a yA N O V Af o l l o w e db yaT u c k e y ’s post test). These
results corroborate that HQNO generally suppresses the
growth of normal S. aureus populations and provokes
the emergence of SCVs from strains of different origins.
HQNO stimulates biofilm production in normal strains but
does not alter high biofilm production in SCVs
Several pairs of related normal and SCVs strains were used
in order to study the effect of HQNO on biofilm produc-
tion by S. aureus. Fig. 2A shows that SCVs produce signifi-
cantly more biofilm than their normal counterparts. The
use of the strain NewbouldhemB (which is a stable labora-
tory-derived SCV) ensured that SCVs (and not revertants)
are indeed responsible for this increase in biofilm produc-
tion (at least in the case of NewbouldhemB). Furthermore,
as shown in Mitchell et al. [20], supplementation of the
SCV strains CF03 and CF07 with menadione abolished
this phenomenon and thus demonstrated that if there was
a reversion of SCVs to the normal phenotype, the biofilm
production would be greatly reduced.
Besides, the presence of HQNO at 10 μg/ml did stimu-
late biofilm production in the normal strains (Fig. 2B-C).
This observation was statistically significant for the nor-
mal strains ATCC 29213, Newman, Newbould, CF03-L,
CF07-L and CF1A-L whereas HQNO had no detectable
effect on the already high biofilm production of the SCV
strains NewbouldhemB, CF03-S, CF07-S and CF1D-S
(Fig. 2C). Moreover, CF03-L produced significantly more
biofilm than ATCC 29213 and Newman in presence of
HQNO, revealing that the amplitude of the response of
normal strains to HQNO may individually differs (Fig.
2C). Interestingly, an overnight exposure to 10 μg/ml of
HQNO resulted in a significant increase in biofilm pro-
duction (P < 0.05) for strain Newman, CF03-L and
CF1A-L even after sub-culturing strains in HQNO-free
medium (data not shown). This indicates that an expo-
sure of S. aureus to HQNO may result in a sustained
increase in biofilm production. Overall, these results sug-
gest that HQNO increases biofilm production in normal
S. aureus strains and that the sustained effect of HQNO
on biofilm production in subsequent HQNO-free med-
ium may result from the relative increase in the sub-
population of SCVs which are good biofilm producers.
SigB is involved in HQNO-mediated emergence of SCVs
and biofilm production
Strains Newbould and NewbouldΔsigB were used to
determine whether SigB is involved in the emergence of
SCVs and biofilm production under an exposure to
HQNO. Fig. 3A illustrates the ability of HQNO (10 μg/
ml, overnight) to favor the emergence of the SCV phe-
notype only in a sigB
+ background. HQNO significantly
increased the presence of SCVs in strain Newbould, but
not in NewbouldΔsigB ( F i g .3 B ) .T h i sr e s u l tw a sc o n -
firmed with strains SH1000 and 8325-4 (data not
shown), which are isogenic strains with a functional and
dysfunctional SigB system, respectively [36]. Fig. 3C
demonstrates that the presence of HQNO significantly
inhibits the growth of both Newbould and NewbouldΔ-
sigB (P < 0.05 at 24 h of growth for both; two-way
ANOVA followed by a Bonferroni’s post test). However,
the ability of HQNO to increase biofilm formation was
observed with strain Newbould, but not with New-
bouldΔsigB (Fig.3D). These results suggest that, even if
the inhibition of growth caused by HQNO is not influ-
enced by SigB (Fig. 3C), HQNO-mediated emergence of
SCVs and biofilm production is triggered by a SigB-
dependent mechanism (Fig. 3D).
SigB and agr activities are modulated by an exposure to
HQNO
Fig. 4 shows qPCR measurements of the expression of
the genes asp23, fnbA, hld (RNAIII), hla, sarA and gyrB
at the exponential growth phase for strains Newbould
and NewbouldΔsigB exposed or not to HQNO. The
expression of asp23 and fnbA was evaluated in order to
verify the hypothesis that SigB is activated during
HQNO exposure. The gene asp23 is a well-known mar-
ker for SigB activity as for the gene fnbA, although the
transcription of the latter is not exclusively influenced
by SigB [15,19,22,37]. Fig. 4A and 4B show that HQNO
at 10 μg/ml induced SigB activity in strain Newbould, as
revealed by significant increases of asp23 and fnbA
expression. The effect of HQNO on the expression of
asp23 and fnbA was further confirmed with the
sequenced strain Newman (data not shown). These
results suggest that SigB activity is increased by HQNO.
The activity of the agr system is known to be reduced
in SCVs [15,38-41]. We have thus hypothesized that
HQNO exposure would repress the agr quorum-sensing
system due to the general suppression of growth toward
normal strains (likely mediated through the inhibition of
the electron transport chain by HQNO [42]) but also
due to the overall emergence of the SCV sub-population
as seen in Fig. 1. Indeed as expected, Fig. 4C shows that
exposure of Newbould and NewbouldΔsigB to HQNO
significantly repressed the expression of hld (the effector
of the agr system).
With the increased in SigB activity and the reduced
expression of agr observed under exposure to HQNO, it
was also justified to measure the expression of the
a-hemolysin gene hla which can be influenced by both
agr and SigB [36,43]. hla was only significantly repressed
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of HQNO (Fig. 4D). Furthermore, the expression of hla
was, in both exposed and unexposed conditions, signifi-
cantly increased in NewbouldΔsigB in comparison to
Newbould, which confirms the negative influence of
SigB on hla expression [36]. These results show that the
expression of hla is reduced by HQNO and that the
influence of SigB on hla expression under HQNO expo-
sure seems to be predominant over the agr system.
The expression level of sarA was also measured
because of its partial dependency on SigB for expression
[22,23], and its roles in the regulation of virulence factors
expression [24] and in biofilm formation [29]. Fig. 4E
shows that sarA expression is significantly induced by
HQNO in strain Newbould but not in NewbouldΔsigB.
The specificity of the observed modulations in gene
expression was validated by monitoring the impact of
HQNO on the expression of the housekeeping gene gyrB.
The expression of gyrB was not modulated in the differ-
ent conditions tested (Fig. 4F). These results suggest that
HQNO induces the expression of sarA by a SigB-depen-
dent mechanism.
Overall, these results suggest that exposure of S. aur-
eus to HQNO reproduces the transcriptional signature
found in SCVs [12,15,19,20,41] and stimulates biofilm
production by having opposite effects on the activity of
SigB (up) and agr (down) as well as on the expression
of sarA (up by a SigB-dependent mechanism).
P. aeruginosa stimulates biofilm formation and increases
the activity of SigB of a S. aureus CF isolate
In order to ascertain that the effect of HQNO on S. aur-
eus is representative of what may happen when P.
Figure 1 HQNO inhibits the growth of normal S. aureus strains and provokes the emergence of SCVs. (A) Growth curves of the normal
strain CF1A-L (□) and the SCV CF1D-S (●) exposed (dotted lines) or not (solid lines) to 10 μg/ml of HQNO. (B) Pictures show SCV colonies
grown on agar containing a selective concentration of gentamicin following or not an overnight treatment of strain CF1A-L with 10 μg/ml of
HQNO. (C) Relative number of SCV CFUs recovered after 18 h of growth from strains ATCC 29213, Newman, Newbould, CF03-L, CF07-L and
CF1A-L following (black bars) or not (open bars) treatments with 10 μg/ml of HQNO. Data are presented as means with standard deviations
from at least three independent experiments. Results are normalized to the non exposed condition for each strain (dotted line). Significant
differences between untreated and HQNO-treated conditions are shown (*, P < 0.05; **, P < 0.01; ***, P < 0.001; unpaired t-test).
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co-infection, we conducted experiments in which S. aur-
eus was exposed to supernatants from overnight cultures
of P. aeruginosa as well as experiments using a double
chamber co-culture model. We used the E. coli strain
K12 in control experiments to ensure that the observed
effect was specific to P. aeruginosa and was not only
caused by the close proximity of a Gram-negative
bacterium or non specific alterations of the growth
medium. We used E. coli because it is known that this
bacterium does not produce HQNO (E. Déziel, unpub-
lished data). Fig.5A shows that P. aeruginosa PAO1 inhi-
bits the growth of the S. aureus strain CF1A-L whereas
this phenomenon was not observed with E. coli K12.
The supernatant collected from an overnight culture of
PAO1 significantly inhibited the growth of S. aureus.
This growth inhibition was accompanied by a significant
increase in biofilm production (Fig. 5B). Fig. 5C shows
that when S. aureus CF1A-L was co-cultured with
PAO1 for 6 h, significantly more SCVs were recovered
than that seen when the co-culture was done with
E. coli K12. Of striking interest, the co-cultivation of
S. aureus CF1A-L with P. aeruginosa PAO1 specifically
and significantly increased the expression of asp23.
These results confirm that P. aeruginosa has the poten-
tial to specifically inhibit the growth, stimulate biofilm
production, favor the emergence of the SCV phenotype
and increase the activity of SigB in non-SCV S. aureus
strains.
HQNO from P. aeruginosa stimulates S. aureus biofilm
production by a SigB-dependent mechanism
We used the pqsA and pqsL mutants derived from
P. aeruginosa PA14 to further confirm the specific effect
of HQNO on biofilm production by S. aureus. The pqsA
mutant does not produce any 4-hydroxy-2-alkylquino-
lines (HAQs) at all [44,45], whereas the pqsL mutant is
specifically altered in HQNO biosynthesis [46]. Thus,
we have used both pqsA and pqsL mutants in order to
distinguish the global impact of all P. aeruginosa HAQs
from the specific impact ofH Q N Oo nb i o f i l mp r o d u c -
tion by S. aureus.F i g .6 As h o w st h a tt h eg r o w t ho ft h e
pqsA and pqsL mutants is not impaired compared to
that of the parental strain PA14, thus excluding varia-
tions in supernatant composition caused by differences
in growth rates among strains. Fig. 6B shows that the
supernatant from an overnight culture of P. aeruginosa
PA14 stimulates biofilm production by S. aureus CF1A-
Li nc o m p a r i s o nt ot h es u p e r n a t a n tf r o mt h epqsL
mutant (specific HQNO-minus strain). The effect of dif-
ferent doses of supernatants from overnight cultures of
P. aeruginosa PA14, the pqsA mutant, the pqsL mutant
or E. coli K12 on biofilm production by S. aureus
CF1A-L is shown in Fig. 6C. While supernatants from
both mutants significantly induced less biofilm produc-
tion in comparison to PA14, this attenuated effect was
more pronounced for the pqsA mutant (negative for the
production of all HAQs) than the pqsL mutant. This
result can be explained by the fact that other HAQs
secreted by P. aeruginosa, although less potent than
HQNO, can also have a growth-inhibitory activity
against S. aureus [47]. Noteworthy, all three strains of P.
aeruginosa stimulated biofilm production in comparison
Figure 2 HQNO stimulates biofilm production in normal strains
but does not alter high biofilm production in SCVs. (A) Relative
biofilm production in related normal (open bars) and SCV (grey
bars) strains. Results are normalized to the normal strain for each
pair (dotted line). (B) Pictures show the biofilm formation of the
normal strain CF1A-L in the absence or in the presence of HQNO as
detected by crystal violet staining. (C) Relative biofilm production in
strains exposed (black bars) or not (open bars) to 10 μg/ml of
HQNO. Results are normalized to the unexposed condition for each
strain (dotted line). Data are presented as means with standard
deviations from at least three independent experiments. Significant
differences between normal and SCV strains (-L and -S suffixes,
respectively) or between unexposed and HQNO-exposed conditions
are shown (*, P < 0.05; **, P < 0.01; ***, P < 0.001; unpaired t-test).
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ducts can indeed stimulate biofilm production by
S. aureus.
Fig. 6D confirms that HQNO from the supernatant of
strain PA14 stimulates biofilm production by a SigB-
dependent mechanism. The increase in biofilm production
observed when S. aureus Newbould is in contact with the
supernatant from PA14 is significantly higher than that
seen with supernatants from the pqsA and pqsL mutants.
Surprisingly, both mutants did not significantly stimulate
biofilm production by Newbould as that observed for
CF1A-L, suggesting that differences between S. aureus
strains may exist in respect to their response to the pre-
sence of non-HQNO exoproducts. As expected, biofilm
production by NewbouldΔsigB in contact with superna-
tants from the three P. aeruginosa strains was significantly
inferior to that observed using the PA14 supernatants with
strain Newbould. Moreover, supernatants from PA14
generally did not significantly stimulate biofilm production
by NewbouldΔsigB in comparison to supernatants from
pqsA and pqsL mutants, which confirms that SigB is
involved in HQNO-mediated S. aureus biofilm produc-
t i o n .O v e r a l l ,t h er e s u l t so ft h i ss e c t i o ns u p p o r tt h e
hypothesis that HQNO from P. aeruginosa stimulates bio-
film production by S. aureus through a SigB-dependent
mechanism.
Discussion
We found that the P. aeruginosa exoproduct HQNO
increases the production of biofilm by S. aureus.T h e
effects on biofilm production, as well as on growth,
were only seen on normal strains whereas the already
high biofilm formation and slow growth rate of SCVs
were not altered by the presence of HQNO. It is known
that HQNO specifically inhibits electron transport in
G r a m - p o s i t i v eb a c t e r i a[ 4 2 ]a n di t si m m e d i a t ea c t i o n
Figure 3 SigB is involved in HQNO-mediated emergence of SCVs and biofilm production. (A) Pictures show SCV colonies grown on agar
containing a selective concentration of gentamicin following or not an overnight exposure to 10 μg/ml of HQNO for strains Newbould and
NewbouldΔsigB. (B) Relative number of SCV CFUs recovered after 18 h of growth for strains Newbould and NewbouldΔsigB in the presence
(black bars) or not (open bars) of 10 μg HQNO/ml. Results are normalized to unexposed Newbould (dotted line). Data are presented as means
with standard deviations from at least three independent experiments. Significant differences between unexposed and HQNO-exposed
conditions (*, P < 0.05), and between strains in the same experimental condition (Δ, P < 0.05) were revealed by a one-way ANOVA with tuckey’s
post test. (C) Growth curves of Newbould (□) and NewbouldΔsigB (●) exposed (dotted lines) or not (solid lines) to 10 μg/ml of HQNO. (D)
Relative biofilm formation as a function of the concentration of HQNO for strains Newbould (open bars) and NewbouldΔsigB (grey bars). Results
are normalized to the unexposed condition for each strain (dotted line). Data are presented as means with standard deviations from two
independent experiments. Significant differences between Newbould and NewbouldΔsigB for each concentration of HQNO are shown (*, P <
0.05; **, P < 0.01; two-way ANOVA with bonferroni’s post test).
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tion and growth to a similar level to that observed in
SCVs. Interestingly, our results also indicate that
HQNO provokes a sustained stimulatory effect on the
production of biofilms by S. aureus. We indeed found
that a pre-treatement of S. aureus with HQNO still led
to a subsequent increase in biofilm formation even after
HQNO removal. This sustained effect is probably asso-
ciated with the increased proportion of the sub-popula-
tion of SCVs resulting from HQNO exposure. An
exposure of S. aureus to HQNO may thus, in addition
to its immediate effect, favor the emergence of SCVs
having a long-term impact on biofilm formation.
Aminoglycosides are also known to favor the emergence
of SCVs [12] and are often used in CF patient care [1].
Interestingly, a synergistic effect between HQNO and
tobramycin for the formation of S. aureus SCVs was pre-
viously observed by Hoffmann et al. [2]. It is thus possible
that the administration of aminoglycosides to CF patients
co-infected with both S. aureus and P. aeruginosa further
increases the formation of biofilm by S. aureus. Besides, it
is well known that the abnormal function of the CF trans-
membrane conductance regulator (CFTR) protein in CF
patients has profound consequences on the airway phy-
siology and it will be of great interest to determine
whether other parameters related to the CF airways influ-
ence the emergence of SCVs and the production of bio-
films by S. aureus. The expression of virulence factors in
S. aureus is indeed controlled by diverse and complex reg-
ulatory networks in a time- and environment-dependent
manner, being influenced for example by ionic forces, pH
and O2 [48]. Consequently, it is likely that S. aureus speci-
fically responds to the particular environment of CF air-
ways. Whether this response is SigB-dependent and will
lead to the emergence of SCVs and biofilm production
remains to be determined.
Naturally-occurring mutations altering the activity of
virulence regulators in S. aureus have been previously
reported [36,49-52]. Our results suggest that the inacti-
vation of sigB will importantly influence the outcome of
Figure 4 SigB and agr activities are modulated by an exposure to HQNO. Relative expression ratios for the genes asp23 (A), fnbA (B), hld
(C), hla (D), sarA (E) and gyrB (F) were evaluated by qPCR for strains Newbould and NewbouldΔsigB grown to the exponential phase in the
presence (black bars) or in the absence (open bars) of 10 μg/ml of HQNO. Results are normalized to unexposed Newbould (dotted line). Data
are presented as means with standard deviations from at least three independent experiments. Significant differences between the unexposed
and HQNO-exposed conditions (*, P < 0.05; ***, P < 0.001) and between Newbould and NewbouldΔsigB for the same experimental condition (Δ,
P < 0.05; ΔΔ, P < 0.01; ΔΔΔ, P < 0.001) were revealed by one-way ANOVA followed by the tuckey’s post test.
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and S. aureus. We are currently studying S. aureus iso-
lates from CF patients co-infected with P. aeruginosa
which are not influenced by the presence of P. aerugi-
nosa. This, in addition to the observation that differ-
ences between S. aureus strains exist relative to their
response to HAQs (Fig. 6C and 6D), suggest that S. aur-
eus strains isolated from CF patients may adapt or
evolve toward a long-term coexistence with P. aerugi-
nosa. Whether this involves mutations in sigB or any
other genes encoding regulators is now under investiga-
tion and will greatly help to understand the dynamic
behavior and the adaptation of S. aureus in response to
the CF airway environment as well as to the presence of
P. aeruginosa.
The effect of HQNO on the regulators SarA, agr and
SigB suggests that several virulence factors should be
influenced by the presence of HQNO. A concomitant
activation of SigB and repression of agr should result in
t h eu p - r e g u l a t i o no fav a r i e ty of cell-surface proteins
(such as FnBA) involved in adhesion to host tissues, and
in the repression of several exotoxins (such as a-hemoly-
sin, Hla) and proteolytic enzymes [22,25]. It is then
tempting to speculate that the presence of HQNO will
Figure 5 P. aeruginosa stimulates biofilm formation and increases the activity of SigB of a S. aureus CF isolate. (A) CFU/ml recovered
after 48 h of growth of CF1A-L (open bar) and CF1A-L in the presence of supernatants from overnight cultures of P. aeruginosa PAO1 (black
bar) or of E. coli K12 (hatched bar). The picture shows the specific inhibitory effect of P. aeruginosa on the growth of S. aureus. (B) Relative
biofilm production by CF1A-L grown in the presence of supernatants from overnight cultures of P. aeruginosa or E. coli. Pictures show the
biofilm formation of CF1A-L in the absence or in the presence of culture supernatants of P. aeruginosa or E. coli as detected by crystal violet
staining. (C) Relative number of SCV CFUs recovered after 6 h of growth for S. aureus CF1A-L in co-culture with PAO1 or K12 as determined
using the double chamber co-culture model. (D) Relative expression ratios for the gene asp23 were evaluated by qPCR for CF1A-L in co-culture
with PAO1 or K12. For B, C and D, results are normalized to unexposed CF1A-L (dotted line). Data are presented as means with standard
deviations from three independent experiments. Significant differences between unexposed CF1A-L and the exposed conditions (*, P < 0.05; ***,
P < 0.001) and between CF1A-L exposed to PAO1 or K12 (Δ, P < 0.05; ΔΔΔ, P < 0.001) were revealed by one-way ANOVA followed by the
tuckey’s post test.
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Page 8 of 15Figure 6 HQNO from P. aeruginosa stimulates biofilm production of S. aureus strains by a SigB-dependent mechanism.( A )G r o w t h
curves of P. aeruginosa strain PA14 and the pqsA and pqsL mutants. (B) Pictures show relative biofilm production of CF1A-L in the absence or in
the presence of supernatants from overnight cultures of P. aeruginosa PA14 or the pqsL mutant as determined by crystal violet staining. (C)
Relative biofilm production by S. aureus CF1A-L as a function of the proportion of supernatant from overnight cultures of P. aeruginosa PA14, the
pqsA mutant, the pqsL mutant or E. coli K12. Results are normalized to unexposed CF1A-L (dotted line). Significant differences between CF1A-L
+PA14 and the other conditions for each proportion of supernatant are shown (*, P < 0.05; two-way ANOVA with Bonferroni’s post test). (D)
Relative biofilm production by S. aureus strains Newbould and NewbouldΔsigB as a function of the proportion of supernatant from overnight
cultures of P. aeruginosa PA14, the pqsA or the pqsL mutant. Significant differences between Newbould + PA14 and the other conditions for
each proportion of supernatant (*, P < 0.05; two-way ANOVA with Bonferroni’s post test), and between NewbouldΔsigB + PA14 and Newbould
ΔsigB + the pqsA or the pqsL mutant (Δ, P < 0.05; two-way ANOVA with Bonferroni’s post test) are shown. The significant difference between
untreated Newbould and NewbouldΔsigB is also shown (#, P < 0.05; unpaired t-test). Data are presented as means with standard deviations from
at least three independent experiments.
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Page 9 of 15prevent S. aureus from disseminating and will rather
favor tissue colonization, biofilm production and invasion
of host cells. It has indeed been suggested that S. aureus
FnBPs mediates cellular invasion [53,54] whereas the
capacity of the bacterium to remain intracellular is
helped by the repression of hla [ 5 5 ] .A c c o r d i n g l y ,w e
showed that an exposure of S. aureus to HQNO up-regu-
lates the expression of fnbA and represses the expression
of hla. However, whether or not HQNO and P. aerugi-
nosa increase the invasion of host cells by S. aureus
remains to be confirmed. Interestingly, O’Neil et al. [32]
have recently demonstrated that the FnBPs are also
involved in the ica-independent mechanism of biofilm
formation. It is thus possible that FnBPs are directly
responsible for the observed HQNO-mediated SigB-
dependent increase in biofilm production and, more spe-
cifically, FnBPA which is under the control of SigB for
expression [15,19,22,37]. As such, the FnBPs would
represent the main effectors for both biofilm formation
and cellular invasion in S. aureus SCVs.
HQNO may be one of several bacterial exoproducts
influencing S. aureus during polymicrobial infections.
Our results and those of Machan et al. [47] suggest that
other HAQs may also affect S. aureus, although not as
efficiently as HQNO. Moreover, it is known that other P.
aeruginosa exoproducts such as pyocyanin have an inhi-
bitory activity against the electron transport chain of S.
aureus [13]. Loss of pyocyanin production has been asso-
ciated with mutations in the pqsA-E genes [45,56], which
may provide an additional explanation for the different
effects of the pqsA and pqsL mutants we have observed
on the growth (data not shown) and biofilm formation of
S. aureus ( F i g .6 C ) .F u r t h e r m o r e ,Q a z iet al. [7] found
that an N-acyl-homoserine-lactone from P. aeruginosa
antagonizes quorum sensing and virulence gene expres-
sion in S. aureus.M o r ep r e c i s e l y ,i tw a ss h o w nt h a tt h e
3-oxo-C12-HSL interacts with the cytoplasmic membrane
of S. aureus and down-regulates both sarA and agr
expression. Although we also observed here a down-reg-
ulation of agr, the HQNO-mediated up-regulation of
sarA suggests further complexity in the response of S.
aureus to P. aeruginosa exoproducts. It is possible that
the outcome of the S. aureus-P. aeruginosa interaction is
dependent on the amount and the types of exoproducts
secreted by the specific strain of P. aeruginosa interacting
with S. aureus.
It should be kept in mind that the diversity of diffusible
bacterial signals and their role in interspecies communi-
cation are just beginning to be appreciated [9] and that
potentially numerous other bacterial species may be
interacting with S. aureus, especially during infectious
diseases. It is then likely that S. aureus interacts with
other bacterial genus than Pseudomonas during infection
of the airways of CF patients. As an example, the CF
pathogen Burkholderia cepacia also produces N-acylho-
moserine lactones [57] and some Burkholderia species
are able to synthesize HAQ analogues [58]. Nevertheless,
the observation that P. aeruginosa favors the emergence
of SCVs and biofilm production by S. aureus is likely to
have a significant clinical impact. The clinical conse-
quences may actually surpass the previously anticipated
formation of aminoglycoside-resistant SCVs by Hoffman
et al. [2]. Persistence of bacteria in chronic infections has
been associated with biofilm production [1,59] and bio-
films are known to confer protection from host defenses
and antibiotic treatments at large [34,60]. In the cystic
fibrosis context, where obstructive infections worsen the
health prognosis of patients, the clinical significance of
biofilm production by normal S. aureus and SCV strains
will need to be further investigated.
Conclusions
This study strongly supports the hypothesis that P. aeru-
ginosa influences the pathogenicity of S. aureus by pro-
ducing HQNO, which favors the acquisition of the SCV
phenotype through the activation of the stress- and
colonization-related S. aureus alternative sigma factor B.
Although several P. aeruginosa exoproducts may poten-
tially influence S. aureus,o u ro b s e r v a t i o n sw i t hp u r e
HQNO were confirmed and supported by experiments
using whole supernatants from two P. aeruginosa strains
as well as mutants unable to produce HQNO. Consider-
ing that biofilms and SCVs are both suspected to play a
role in chronic infections of CF airways, the observation
that P. aeruginosa increases the emergence of SCVs and
biofilm formation by S. aureus may influence the patient
health prognosis. New therapeutic strategies should aim
at preventing interspecies interactions and the develop-
ment of specific phenotypes such as biofilm-producing
SCVs in order to reduce the likelihood of chronic
infections.
Methods
Bacterial strains and growth conditions
The relevant characteristics of the strains used in this
study are shown in Table 1. Staphylococcus aureus
A T C C2 9 2 1 3 ,N e w m a na n dN e w b o u l dw e r eu s e da s
representatives of prototypical control strains. New-
bouldΔsigB and NewbouldhemB, in which the genes sigB
or hemB had been disrupted by the ermA cassette
[15,17], were used to evaluate the importance of SigB in a
prototypical background and to generate a stable SCV,
respectively. CF03-L/CF03-S, CF07-L/CF07-S and CF1A-
L/CF1D-S are related pairs of strains co-isolated from CF
patients, which respectively have a normal and a SCV
phenotype. The genetic relatedness of each strain among
the pairs was confirmed by the analysis of multiple loci
with a variable number of tandem repeats (see below).
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Page 10 of 15Except where otherwise stated, S. aureus strains were
grown in brain heart infusion (BHI) broth (BD, ON,
Canada). The use of BHI to study our SCV strains as well
as in the experiments involving quantification of SCVs is
validated in the Additional file 1. Pseudomonas aerugi-
nosa PAO1 [61], PA14 [62], the PA14-derived pqsA and
pqsL mutants [44,46] and Escherichia coli K12 were
grown in trypticase soy broth (TSB) (BD, ON, Canada).
Multiple-locus variable-number of tandem repeat analysis
(MVLA) of strains co-isolated from CF patients
The relatedness of each of the co-isolated strains within
the pairs CF03-L/CF03-S, CF07-L/CF07-S and CF1A-L/
CF1D-S was confirmed by MVLA as described by Sabat
et al. [63]. The strains of each pair had identical MVLA
patterns.
Growth curves
S. aureus overnight cultures were used at an A595 nm of 0.1
to inoculate BHI broths supplemented or not with 10 μg/
ml of HQNO (Axxora, CA, USA). Cultures were then
incubated at 35°C/225 RPM and samples were taken at
different time points for determination of CFU by spread-
ing 10-fold dilutions on trypticase soy agar (TSA) plates
(BD, ON, Canada). Plates were incubated at 35°C for 24
and 48 h for normal and SCV strains, respectively. For the
growth curves of P. aeruginosa PA14 and the pqsA and
pqsL mutants, overnight cultures were used to inoculate
TSB. Cultures were then incubated at 35°C/225 RPM and
samples were taken at specified time points in order to
evaluate their turbidity at A595 nm.
Quantification of SCVs
We have quantified SCVs by taking advantage of their
reduced susceptibility to aminoglycosides as described
elsewhere with few modifications [20,64,65]. A 1:100
dilution of overnight broth cultures was used to inocu-
late BHI broths supplemented or not with 10 μg/ml of
HQNO. Cultures were incubated 18 h and then adjusted
to an A595 nm of 2.0 in PBS at 4°C. Determination of
SCV CFUs was done by serial dilution plating. SCV
counts were obtained by plating on TSA containing gen-
tamicin (Sigma-Aldrich, ON, Canada) at 4 μg/ml fol-
lowed by an incubation of 48 h at 35°C. As shown in
Additional file 2, this concentration of gentamicin is
selective for SCVs as it allows the growth of SCVs, but
not that of normal strains. The frequency of SCVs is
defined as the number of SCVs per total CFU counts on
antibiotic-free TSA. The pinpoint colonies detected by
this gentamicin-plate method were confirmed to be
SCVs by streaking several of them on TSA plates (See
Additional file 3). We have also evaluated the auxo-
trophism (as described below) of several HQNO-
induced SCVs generated from strains CF1A-L and
CF07-L in order to further validate the ability of this
technique to detect typical SCVs (see Additional file 4).
Antibiotic susceptibility
The minimal inhibitory concentrations (MICs) of genta-
micin for all strains were determined by a broth micro-
dilution technique, following the recommendations of
the Clinical and Laboratory Standards Institute (CLSI)
Table 1 Bacterial strains used in this study
Strains Relevant characteristics Auxotrophism References
S. aureus strains
ATCC 29213 Laboratory strain, normal - -
Newman ATCC 25904 Laboratory strain, normal - -
Newbould ATCC 29740 Laboratory strain, normal - -
NewbouldΔsigB Newbould ΔsigB::emrA; Erm
R - [15]
NewbouldhemB Newbould hemB::ermA; Erm
R Hemin [17]
CF03-S SCV strain isolated from a CF patient Menadione [15]
CF03-L Normal strain co-isolated with CF03-S - This study
CF07-S SCV strain isolated from a CF patient Menadione [15]
CF07-L Normal strain co-isolated with CF07-S - This study
CF1D-S SCV strain isolated from a CF patient Unknown This study
CF1A-L Normal strain co-isolated with CF1D-S - This study
P. aeruginosa strains
PAO1 Laboratory strain - [61]
PA14 Clinical strain, Rif
R - [62]
pqsA PA14 pqsA::TnphoA; Rif
R,K m
R - [44]
pqsL PA14 ΔpqsL; Rif
R - [46]
E. coli strains
K12 Laboratory strain - -
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Page 11 of 15guidelines [66], except that the incubation period was
extended to 48 h and that the medium used was BHI in
order to allow SCVs to reach maximal growth.
Auxotrophism of SCVs
In the context of SCVs, auxotrophism is defined as the
requirement of specific compounds in order to regain a
normal growth phenotype [41]. An agar diffusion
method was used to characterize the auxotrophism of
SCVs using hemin or menadione (10 μge a c h / w e l l )o n
an inoculated Mueller-Hinton agar (MHA) plate. Thy-
midine at 1.5 μg/well was also tested as previously
described [67]. Auxotrophy for specific supplements was
detected by a zone of normal growth surrounding the
well after 18 h of incubation at 35°C. The photography
of the Additional file 5 shows the normal growth of
NewbouldhemB in proximity of a well loaded with
hemin as an example of a positive auxotrophism result.
Preparation of supernatants from P. aeruginosa and E. coli
strains
Overnight cultures were used to inoculate TSB at a dilu-
tion of 1:100. Cultures were then incubated 20 h at 35°C/
225 RPM before collecting the culture supernatants by
centrifugation. Similar culture conditions were previously
shown to allow maximal production of HQNO by P. aer-
uginosa PAO1 [68]. The supernatants were then filter-
sterilized using 0.22 μ pore size (Millipore, MA, USA)
and used immediately. The sterility of the supernatants
was confirmed by plating samples on TSA plate.
Biofilm formation
For studying the effect of HQNO on biofilm production
by S. aureus, three colonies grown on blood agar plates
were used to inoculate BHI broths containing 0.25% glu-
cose with or without 10 μg/ml of HQNO and cultures
were incubated for 18 h. These cultures were used to
adjust an appropriate volume of BHI-0.25% glucose to 0.5
Mcfarland for transfer into wells of a flat-bottom polystyr-
ene microtiter plate containing half volume of the same
medium with or without HQNO (final concentration 10
μg/ml). For experiments evaluating the effect of culture
supernatants from P. aeruginosa and E. coli on S. aureus
biofilm production, a S. aureus 0.5 Mcfarland suspension
was prepared in BHI-0.5% glucose and transferred into
wells of a microtiter plate containing half the volume of
the supernatant to be tested. The plates were incubated at
35°C for 48 h. The supernatant was then discarded and
the wells were delicately washed three times with 200 μlo f
PBS. The plates were dried, stained for 30 min with crystal
violet, washed twice with 200 μl of water and allowed to
dry again. A volume of 200 μl of 95% ethanol was added
to each well and plates were incubated at room tempera-
ture for 1 h with frequent agitation. The absorbance of
each well was then measured at 560 nm using a plate
reader (Bio-Tek Instruments). The biofilm formation of
each culture tested was evaluated in four replicates. The
A560 nm values (non-normalized data) representing the
biofilm production for each of the strains used in Fig. 2
can be seen in the Additional file 6.
Quantitative PCR (qPCR)
In order to evaluate the effect of HQNO (10 μg/ml) on
S. aureus gene expression, overnight cultures were used
to inoculate broth at an A595 nm of 0.1. Bacteria were
then grown until the unexposed control culture reached
an A595 nmbetween 0.9 and 1.0. Bacteria were collected
and treated with RNAprotect (QIAGEN, ON, Canada).
RNA was extracted from the cell pellets after treatment
with lysostaphin (Sigma-Aldrich) (200 μg/ml, 1 h) using
the RNeasy Mini kit and the RNase-free DNase set
(QIAGEN). A second DNase treatment was also done
with the DNA-free kit (Applied Biosystems/Ambion,
CA, USA). One μg of total RNA was reverse transcribed
with 0.5 mM deoxynucleotide phosphate, 50 ng of ran-
dom hexamers and 200 U of Invitrogen Superscript II
reverse transcriptase, according to the manufacturer’s
recommendations (Invitrogen, ON, Canada). RNA was
hydrolyzed and the cDNAs were purified with the QIA-
quick PCR purification kit (QIAGEN). One microliter of
the cDNA preparation was amplified on the Stratagene
MX3000P Real-Time PCR instrument with the Jump
Start Taq DNA polymerase (Sigma-Aldrich), SYBR


























Reaction mixtures were denatured for 10 min at 95°C,
followed by 35 cycles of 30 s at 95°C, 1 min at 60°C and
1 min 30 s at 72°C. Dissociation and standard curves
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of reactions. cDNA synthesis reactions without reverse
transcriptase were also routinely carried out. The rela-
tive expression ratios were calculated by using the cycle
threshold (Ct) of the 16S RNA or gyrB of each condition
as the calibrator (n-fold expression = 2
-ΔCt,w h e r eΔCt
represents the difference between the Ct of the gene stu-
died and the Ct of the 16S RNA or gyrB for each
condition).
Double chamber co-culture model
Overnight cultures of S .a u r e u s ,E .c o l iand P. aerugi-
nosa in TSB were used to inoculate bottom (S. aureus,
E. coli or P. aeruginosa)o rt o p( S. aureus)c h a m b e r so f
0.4-μm pore polycarbonate membrane inserts (Transwell
[Corning, MA, USA]). S. aureus was inoculated at an
A595 nm of 0.01, whereas P. aeruginosa or E. coli were
inoculated at an A595 nm of 0.1. The cultures were incu-
bated at 35°C/80 RPM for 6 h and samples were taken
for SCV enumeration and total CFU counts as well as
for RNA extraction. No bacterial cross-contamination
was detected by culture plating up to at least 9 h of
incubation.
Statistical analysis
One-way analysis of variance followed by Dunnett’s
multiple comparisons test or Tukey’s multiple compari-
sons test were used when several conditions or strains
were compared at the same time whereas unpaired t-
tests were used when only two conditions were com-
pared. Two-way ANOVA with Bonferroni’sp o s tt e s t s
were used to compare the response of different strains
and/or different conditions as a function of the concen-
tration of HQNO or bacterial culture supernatants. Sta-
tistical analyses of qPCR data were done on mean ΔCt.
CFU counts or SCV frequencies were transformed in
based-10 logarithm values before being used for statisti-
cal analyses that were carried out with the GraphPad
Prism Software (v.5.00). Statistical tests used for the ana-
lysis of each experiment are specified in figure legends.
Additional file 1: Validation of the use of BHI as the growth
medium to induce and study SCVs. (A) Growth curves expressed in
absorbance at 595 nm for the strains Newbould, NewbouldhemB, CF07-L
and CF07-S. The growth of NewbouldhemB and CF07-S was
supplemented or not with 5 μg/ml of hemin and 1 μg/ml of menadione,
respectively. Results show that SCVs present their slow-growth
phenotype in BHI unless supplemental hemin or menadione is added to
the broth. (B) Pictures of colonies from strains Newbould,
NewbouldhemB, CF07-L and CF07-S grown on BHI agar for 16 hours.
Results show that SCVs retain their slow-growth phenotype on BHIA in
comparison to normal strains. (C) Appearance of the colonies obtained
from the cultures shown in A at the 12-h time point and plated on
Mueller-Hinton agar (MHA) for 36 hours. Results show that normal strains
grow efficiently on MHA whereas SCVs taken from BHI broth (cultures
shown in A and supplemented or not with hemin or menadione) still
present their slow-growth phenotype once plated back on MHA.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2180-10-
33-S1.PDF]
Additional file 2: Minimal inhibitory concentrations (MICs) of
gentamicin for the studied strains. Results of this file show that MICs
of gentamicin for SCVs are of 8 μg/ml whereas those of normal strains
are below 2 μg/ml.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2180-10-
33-S2.PDF]
Additional file 3: Appearance of HQNO-induced SCVs selected on
gentamicin-containing agar and streaked back on TSA plates.
Pictures are showing CF07-L, CF07-S and HQNO-induced SCVs selected
on gentamicin-containing agar and streaked back on TSA plates. The
bottom pictures show streaks of three isolated SCVs on TSA plates. Many
more SCVs were similarly tested and our results showed that at least
85% of the SCVs isolated from gentamicin plates were keeping their
slow-growth phenotype when subsequently grown on TSA without
gentamicin.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2180-10-
33-S3.PDF]
Additional file 4: Auxotrophism found among HQNO-induced SCVs.
Auxotrophism found among HQNO-induced SCVs generated from the
normal cystic fibrosis strains CF07-L and CF1A-L.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2180-10-
33-S4.PDF]
Additional file 5: Growth of NewbouldhemB in proximity of a well
loaded with hemin. Growth of NewbouldhemB in proximity of a well
loaded with hemin as an example of a positive auxotrophism result. The
auxotrophism of NewbouldhemB for hemin is seen by observing normal
growth only within the diffusion zone of a well loaded with hemin.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2180-10-
33-S5.PDF]
Additional file 6: Non-normalized absorbance values at 560 nm
representing biofilm production for each of the strains used in Fig.
2. Non-normalized absorbance values at 560 nm representing biofilm
production for each of the strains used in Fig. 2. Results show that
strains vary in their relative production of biofilms but that for each
related pairs of normal and SCV strains, SCV counterparts always produce
more biofilm than their respective normal strains.
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